ANTCF (Aion Therapeutic) Total Stockholders Equity: $-3.23 Mil (As of Jan. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aion Therapeutic Total Stockholders Equity?

Aion Therapeutic ANTCF Total Stockholders Equity is $-3.23 Mil as of Jan. 2025.

Aion Therapeutic's Total Stockholders Equity for the quarter that ended in Jan. 2025 was $-3.23 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Aion Therapeutic's Book Value per Share for the quarter that ended in Jan. 2025 was $-0.01. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Aion Therapeutic's Debt-to-Equity for the quarter that ended in Jan. 2025 was -0.60.


Aion Therapeutic  (OTCPK:ANTCF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Aion Therapeutic's Book Value per Share for the quarter that ended in Jan. 2025 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Aion Therapeutic's Debt-to-Equity for the quarter that ended in Jan. 2025 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aion Therapeutic Total Stockholders Equity Related Terms


Aion Therapeutic Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Aion Therapeutic's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aion Therapeutic Total Stockholders Equity Chart

Aion Therapeutic Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Total Stockholders Equity
Get a 7-Day Free Trial 1.54 0.32 -1.88 -2.01 -2.82

Aion Therapeutic Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 -2.82 -2.93 -2.95 -3.23
What does a Total Stockholders Equity of $-3.23 Mil mean?
Aion Therapeutic (ANTCF) has a Total Stockholders Equity of $-3.23 Mil as of Jan. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Aion Therapeutic and its competitors.
Is Aion Therapeutic's Total Stockholders Equity too high?
Aion Therapeutic's current Total Stockholders Equity is $-3.23 Mil.
How does Aion Therapeutic's Total Stockholders Equity compare to CBDY and GRPS?
Aion Therapeutic's Total Stockholders Equity of $-3.23 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Aion Therapeutic and its competitors. Aion Therapeutic's current Total Stockholders Equity is $-3.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aion Therapeutic stock overvalued right now?
Aion Therapeutic (ANTCF) has a current Total Stockholders Equity of $-3.23 Mil. The current Total Stockholders Equity is $-3.23 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Aion Therapeutic (ANTCF), the current Total Stockholders Equity is $-3.23 Mil as of Jan. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aion Therapeutic Business Description

Address 700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8
Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery. During the year ended the Company had one operating segment, being health and wellness, dedicated to delivering state-of-the-art water filtration solutions. Geographically company earns revenue from USA.